Valuation: Matinas BioPharma

Market Cap 2.6M 2.27M 2.14M 1.95M 3.66M 249M 3.66M 25.64M 9.89M 127M 9.77M 9.55M 409M P/E 2024
-0.1x
P/E 2025 -0.29x
Enterprise Value -44.38K -38.78K -36.45K -33.26K -62.43K -4.24M -62.44K -437K -169K -2.17M -167K -163K -6.98M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
76.25%
Yield 2024 *
-
Yield 2025 -
1 week+7.45%
Current month-10.27%
1 month-9.72%
3 months-72.71%
6 months-72.28%
Current year-69.73%
1 week 0.15
Extreme 0.154851
0.18
1 month 0.15
Extreme 0.15051
0.21
Current year 0.15
Extreme 0.15051
0.91
1 year 0.15
Extreme 0.15051
2.02
3 years 0.15
Extreme 0.15051
44.5
5 years 0.15
Extreme 0.15051
80.5
10 years 0.15
Extreme 0.15051
199.5
Manager TitleAgeSince
Chief Executive Officer 52 2018-03-15
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 52 2025-03-13
Director/Board Member 61 2025-02-04
Director/Board Member 55 2025-03-10
Date Insider Type Main position Quantity % Market Cap. Importance
4/30/25 Free

Chief Executive Officer

70,100 1.3780%
4/30/25 Free

Director

11,600 0.2280%
4/30/25 Free

Director

11,600 0.2280%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+7.45%-90.86%-97.16% 2.6M
+0.06%+7.20%+54.04%+111.13% 74.27B
-2.29%-1.51%+33.30%+75.15% 61.21B
+0.28%+7.27%+31.74%+23.80% 27.55B
-1.86%-3.27%-18.44%+359.93% 26.38B
-1.04%+3.87%+1.29%-3.47% 25.34B
+0.57%+3.66%+25.59%-9.08% 20.84B
-1.47%+4.46%-8.09%+513.33% 14.94B
+1.29%-2.49%+163.31%+333.06% 15.17B
-2.68%-0.37%+42.10%+159.14% 14.41B
Average -0.71%+3.95%+23.40%+146.58% 28.01B
Weighted average by Cap. -0.83%+3.08%+35.59%+134.74%

Financials

2024 2025
Net sales - -
Net income -24.25M -21.19M -19.92M -18.18M -34.11M -2.32B -34.12M -239M -92.25M -1.18B -91.07M -89.08M -3.82B -10.34M -9.04M -8.5M -7.75M -14.55M -989M -14.56M -102M -39.35M -505M -38.85M -38M -1.63B
Net Debt -4.39M -3.84M -3.61M -3.29M -6.18M -420M -6.18M -43.27M -16.7M -214M -16.49M -16.12M -691M -2.64M -2.31M -2.17M -1.98M -3.72M -253M -3.72M -26.07M -10.06M -129M -9.93M -9.72M -416M
Logo Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Employees
2
Date Price Change Volume
26-09-23 US$0.1774 +0.23% 288,767
26-09-22 US$0.1770 +1.78% 205,844
26-09-21 US$0.1739 +8.42% 292,402
26-09-18 US$0.1604 -1.60% 426,604
26-09-17 US$0.1630 -1.27% 674,340

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MTNB Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!